Merck Blocked From Selling New Keytruda Shot In Europe After Court Loss
Legal·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Merck & Co. was blocked from selling a new injectable version of its blockbuster cancer drug Keytruda in several European countries. This decision represents a setback to the drugmaker’s efforts to extend its most important franchise ahead of looming patent expirations.
The ruling comes as Merck faces challenges in maintaining its market position for Keytruda, which has been a significant revenue driver for the company. The court's decision underscores the competitive landscape in the pharmaceutical industry, particularly for cancer treatments.
Merck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Merck & Co. was blocked from selling a new injectable version of its blockbuster cancer drug Keytruda in several European countries, dealing a setback to the drugmaker’s efforts to extend its most”
Bloomberg — Merck’s New Keytruda Shot Blocked in Europe After Court Loss